TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04341623

Intervention type: OTHER
Group type: OTHER
Intervention: Cetaphil Pro Eczema moisturizer
Description: All 30 patients to receive

Intervention type: OTHER
Group type: OTHER
Intervention: Cetaphil Pro Eczema moisturizer
Description: All 30 patients to receive

Intervention type: OTHER
Group type: OTHER
Intervention: Cetaphil Pro Eczema moisturizer
Description: All 30 patients to receive
Study: NCT06102252

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel/carboplatin
Description: Dose dense paclitaxel/carboplatin
Study: NCT04721015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-637
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-637
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-637
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-637
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-637
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Oral Tablets
Study: NCT06008249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate 400 MG
Description: Lithium carbonate vs placebo (2:1)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lithium Carbonate 400 MG
Description: Lithium carbonate vs placebo (2:1)
Study: NCT05508672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-Centered eHealth Smoking Cessation Intervention (CCeSCI)
Description: We will equip CCeSCI with both core eHealth features and provider-side intervention. Patients assigned to the intervention group will receive a series of online interactive and personalization technologies, including an algorithm-based video curriculum with auto-texting, backstage monitoring system etc. Besides, the patients will also have the face-to-face meetings with community health workers. Provider-side intervention includes training for community workers, WeChat group discussion, and performance-based incentives. The training aims to provide essential skills for community workers so that they can provide face-to-face meetings with smokers during the first 3 months of quitting to prevent or revert relapse in a timely and proactive manner.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional smoking is harmful education
Description: In the control group, the participants will receive traditional smoking is harmful education video, which is recorded by the clinical physicians.
Study: NCT04341623

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Electronic interaction
Description: 10 patients to electronic surveys about moisturizer use

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: GPSkin
Description: Measuring moisture in the skin
Study: NCT05447403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing gum combined with WeChat enhanced instructions
Description: Patients in the chewing gum and WeChat group are advised to chew one piece of sugarless gum for 20 minutes after drinking each 1 liter PEG. They also receive enhanced instructions via WeChat before two days and one day of colonoscopy to further inform how to chew gum and highlight the importance of adequate bowel preparation.
Study: NCT06437834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information Sheet
Description: Information sheet describing the importance of vaccines and preventive care as well as contact information for patient navigators.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information Sheet
Description: Information sheet describing the importance of vaccines and preventive care as well as contact information for patient navigators.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-touch connect
Description: Engagement with a patient navigator.
Study: NCT06513455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine was administered 1000 mg D1、D8、D15，iv. q4w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Liposome（60mg/m2）
Description: irinotecan Liposome was administered 60mg/m2, D1，iv. q2w
Study: NCT04827381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Annotated Audio
Description: In addition to usual care, patients will be given access to an annotated audio-based PHL, HealthPal to listen to outside of the clinic. HealthPAL will allow participants to replay the audio recording of their clinic visit which will be annotated with key information discussed (e.g., medications). The recording will also contain hyperlinks related to annotations, that will direct participants to the online health information resource at Medline Plus. Access to their HealthPAL can also be shared with a caregiver.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audio
Description: In addition to usual care, patients will also be given access to an audio-based PHL, HealthPal to listen to outside of the clinic. HealthPAL will allow participants to replay the audio recording of their clinic visit (no annotations or hyperlinks). Access to their HealthPAL can also be shared with a caregiver.
Study: NCT04899765

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Description: It is an attenuated live bacterial vaccine. This vaccine is a freeze-dried product that must be reconstituted.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles vaccine
Description: It is an attenuated live virus vaccine. This vaccine is a freeze-dried product that must be reconstituted.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT05766839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patiromer
Description: Patiromer will be given once daily; In Cohort 3, depending on the dose and the study participant's age, the total daily dose might be split
Study: NCT05844124

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise for Knee Osteoarthritis -(Land Based Treadmill or Community Walking)
Description: Standard-of-care Land-based walking exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise for Knee Osteoarthritis -(LBPP supported low-load treadmill Walking)
Description: Lower-body positive-pressure (LBPP) supported low-load treadmill walking exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise for Knee Osteoarthritis - (Aquatic Walking)
Description: Aquatic Walking exercise
Study: NCT05738902

Intervention type: OTHER
Intervention: Assessment of compliance to ERAS.
Description: Assessment of compliance to ERAS in postoperative day 2 (POD2) using five indicators based on ERAS items and association with postoperative complications up to 30 days after discharge.
Study: NCT05249816

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373
Description: A single booster injection of NVX-CoV2373 with Matrix-M adjuvant. 0.5 mL injection volume at a dose of 5μg of antigen with 50 μg Matrix-M adjuvant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BBIBP-CorV vaccine
Description: BBIBP-CorV vaccine administered per manufacturer instructions.
Study: NCT05637866

Intervention type: OTHER
Intervention: Soy milk
Description: Soya milk or soymilk, a plant-based beverage that can be sweetened or unsweetened.
Study: NCT05849129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Description: High dose ascorbic acid delivered intravenously

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9% NaCl solution
Study: NCT06564025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pilot program study
Description: To assess program feasibility, acceptability, and preliminary efficacy, we will pilot the intervention with a purposive sample of 50 father-teen pairs (100 participants total). All participants will receive the program.
Study: NCT04609982

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ear plugs
Description: giving half of the patients ear plugs
Study: NCT05458739

Intervention type: DEVICE
Intervention: ClearCoast MR System
Description: The removed specimen is scanned using the ClearCoast MR System.
Study: NCT05081830

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic online intervention
Description: Based on the theoretical proposal of Barlow et al. (2011) a treatment applicable to all anxiety and mood disorders (unipolar depression) will be implemented. The unified protocol incorporates proven emotion-focused psychological techniques (Ellard et al., 2010). The main components are: (1) motivation for change, understanding emotions, and recognition and observation of emotional response; (2) learn to observe experiences, evaluate and reevaluate thoughts; (3) what is emotional avoidance, emotion and behavior, and awareness and tolerance of physical sensations; (4) emotional exposure to physical sensations and situations and achievements, maintenance and prevention of relapses.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TCC online intervention
Description: This program incorporates psychological techniques under the cognitive-behavioral model that have demonstrated their effectiveness in online mode (De la Rosa, 2019; Flores et al., 2014). The main components are: (1) psychoeducation, (2) cognitive restructuring, (3) identification and expression of emotions, (4) assertiveness training and (5) problem solving, and (6) relapse prevention. The order of application of each technique is established by the advisor derived from the formulation of treatment of each case to solve the problems raised, under supervision.
Study: NCT04824833

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus anterior plane block
Description: local anesthetic application between serratus anterior muscle and 5th rib
Study: NCT06384547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRDN-001 10 mg/kg
Description: 5 infusions of VRDN-001 10 mg/kg
Study: NCT06165055

Intervention type: DIAGNOSTIC_TEST
Intervention: DNA Sample Collection + DNA genotyping
Description: Volunteers' oral epithelial cell DNA will be collected using DNA swabs, followed by DNA isolation with the PureLink DNA Isolation Kit. The isolated DNA's quality will be assessed using the Invitrogen QUBIT 4 Fluorometer, and the samples will be stored at -20°C until analysis of specific genetic regions.

Intervention type: DIAGNOSTIC_TEST
Intervention: DNA Sample Collection + DNA genotyping
Description: Volunteers' oral epithelial cell DNA will be collected using DNA swabs, followed by DNA isolation with the PureLink DNA Isolation Kit. The isolated DNA's quality will be assessed using the Invitrogen QUBIT 4 Fluorometer, and the samples will be stored at -20°C until analysis of specific genetic regions.
Study: NCT06384547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRDN-001 3 mg/kg
Description: 5 infusions of VRDN-001 3 mg/kg
Study: NCT05682183

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multi-domain Psychoeducation Self-management Programme
Description: The MPSP is a 5-weeks psychoeducation programme aimed at improving the biopsychosocial health of people with MDD (PMDD). It will be conducted on every Saturday in the morning, afternoon and evening. Specific time of each session will be further discussed with the centre. Each session will last for approximately 45 minutes to 60 minutes and will be capped at 10 participants. The mode of session will be face-to-face (F2F) session conducted at MindCare.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Care management from assigned care manager
Study: NCT06023186

Intervention type: DRUG
Intervention: mavacamten
Description: Study participants will receive mavacamten under the standard of care
Study: NCT06516042

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine
Description: Participants that provide consent to participate in the TDA and are deemed eligible for treatment will receive a course of dihydroartemisinin-piperaquine (DP) if male, and artemether-lumefantrine (AL) if female. They will take the first dose of the treatment under direct observed therapy, and will receive the rest of the tablets to take on their own for days two and three.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine
Description: Participants that provide consent to participate in the TDA and are deemed eligible for treatment will receive a course of dihydroartemisinin-piperaquine (DP) if male, and artemether-lumefantrine (AL) if female. They will take the first dose of the treatment under direct observed therapy, and will receive the rest of the tablets to take on their own for days two and three.
Study: NCT05848583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compleat 1.5
Description: EN Formula
Study: NCT06448364

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07329640
Description: an anti-lymphotoxin beta receptor agonist

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07329640
Description: an anti-lymphotoxin beta receptor agonist

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07329640
Description: an anti-lymphotoxin beta receptor agonist

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07329640
Description: an anti-lymphotoxin beta receptor agonist

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07329640
Description: an anti-lymphotoxin beta receptor agonist

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07329640
Description: an anti-lymphotoxin beta receptor agonist

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07329640
Description: an anti-lymphotoxin beta receptor agonist

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sasanlimab
Description: A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/L2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sasanlimab
Description: A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/L2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: a monoclonal antibody that blocks VEGF

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: a monoclonal antibody that blocks VEGF
Study: NCT05677880

Intervention type: OTHER
Intervention: Study Procedures
Description: Participants will experience~* Neurocognitive Tests and Self-Report Measures~* Clinical Interviews~* Neurological Exam~* MRI screening at baseline, 18 months, 36 months~* Fasted Blood draw

Intervention type: OTHER
Intervention: Study Procedures
Description: Participants will experience~* Neurocognitive Tests and Self-Report Measures~* Clinical Interviews~* Neurological Exam~* MRI screening at baseline, 18 months, 36 months~* Fasted Blood draw

Intervention type: OTHER
Intervention: Study Procedures
Description: Participants will experience~* Neurocognitive Tests and Self-Report Measures~* Clinical Interviews~* Neurological Exam~* MRI screening at baseline, 18 months, 36 months~* Fasted Blood draw

Intervention type: OTHER
Intervention: Study Procedures
Description: Participants will experience~* Neurocognitive Tests and Self-Report Measures~* Clinical Interviews~* Neurological Exam~* MRI screening at baseline, 18 months, 36 months~* Fasted Blood draw
Study: NCT05114928

Intervention type: PROCEDURE
Intervention: Transepithelial Corneal Collagen Cross-linking
Description: Bilateral Transepithelial Corneal Collagen Cross-linking was done for all subjects using power of 9mW/cm2 at 55mm from the cornea for 10 minutes, with a total energy of 5.4j/cm2 using the (CCL VARIO, PESCHKE Trade GmbH, Huenenberg Switzerland), in the period between January 2016 to August 2016.

Intervention type: PROCEDURE
Intervention: Transepithelial Corneal Collagen Cross-linking
Description: Bilateral Transepithelial Corneal Collagen Cross-linking was done for all subjects using power of 9mW/cm2 at 55mm from the cornea for 10 minutes, with a total energy of 5.4j/cm2 using the (CCL VARIO, PESCHKE Trade GmbH, Huenenberg Switzerland), in the period between January 2016 to August 2016.
Study: NCT05227183

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The virtual version of the Social stress task : V-TSST
Description: The task consists in a brief presentation about the abilities of participants followed by an arithmetic task in front of a virtual 3D audience projected and one researcher in a room.First, participants have 5 minutes to prepare an exhibition about their qualities, their strengths and defects, and, why they identify with them. During this period virtual reality shows a closed curtain, and sounds from the audience can be heard. In the second phase, the curtain is raised and the participant must expose his speech during 5 minutes. Audience will remain attentive during 2 minutes, then audience will change to a restless attitude. The third phase consists of subtracting back a two-digit number from a four-digit number, as quickly as possible, starting again if participant makes a mistake. A debriefing of the test is scheduled at the end of the protocol, to remind patients of the purely fictional nature of this test. The visit will only end after a return to the baseline emotional state

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The virtual version of the Social stress task : V-TSST
Description: The task consists in a brief presentation about the abilities of participants followed by an arithmetic task in front of a virtual 3D audience projected and one researcher in a room.First, participants have 5 minutes to prepare an exhibition about their qualities, their strengths and defects, and, why they identify with them. During this period virtual reality shows a closed curtain, and sounds from the audience can be heard. In the second phase, the curtain is raised and the participant must expose his speech during 5 minutes. Audience will remain attentive during 2 minutes, then audience will change to a restless attitude. The third phase consists of subtracting back a two-digit number from a four-digit number, as quickly as possible, starting again if participant makes a mistake. A debriefing of the test is scheduled at the end of the protocol, to remind patients of the purely fictional nature of this test. The visit will only end after a return to the baseline emotional state
Study: NCT05197673

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Theory of planned behaviours (TPB) based intervention
Description: Intervention group will receive TPB-based education program to improve workers' attitude toward SARS-CoV-2 and raise their intention to vaccination and virus testing. The intervention will be implemented at the baseline with measurements repeated at the 3rd month, 6th month and 9th month. The standardized mode of intervention includes face-to-face/online seminar (depends on the COVID-19 situation), message via mobile phone, promotion pamphlet, etc.
Study: NCT05939596

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Bivalent mRNA Vaccine
Description: 100 μg /1.0 mL/dose, slightly milky white and clear liquid, intramuscular injection into the lateral deltoid muscle of the upper arm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 100 μg /1.0 mL/dose, intramuscular injection into the lateral deltoid muscle of the upper arm.
Study: NCT06272162

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR guided radiotherapy
Description: 5 fractions of 10 Gray MRgRT in addition to standard of care
Study: NCT04528264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasound guided
Description: Samsung Mysono U6 machine with LN 15 linear (https://www.samsunghealthcare.com/en/products/UltrasoundSystem/MySono%20U6/General%20Imaging/transducers) probe capable of Musculoskeletal imaging will be used for visualization and location of fracture after which elevation and reduction of fracture will be attempted. The ultrasound probe will be used as described by McCann. Radiographic continuity of periosteal shadow without any step will be taken as end point for reduction and the procedure will be terminated.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional blind reduction technique
Description: Conventional blind reduction technique
Study: NCT05822908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VO659
Description: VO659 is an antisense oligonucleotide targeting CAG repeats in mRNA transcripts
Study: NCT05114928

Intervention type: DIAGNOSTIC_TEST
Intervention: Scheimpflug camera
Description: Pentacam (OCULUS Optikgeräte GmbH, Wetzlar, Germany) was done for all subjects at baseline and annually after TE-CXL till 5 years of follow-up.

Intervention type: DIAGNOSTIC_TEST
Intervention: Scheimpflug camera
Description: Pentacam (OCULUS Optikgeräte GmbH, Wetzlar, Germany) was done for all subjects at baseline and annually after TE-CXL till 5 years of follow-up.
Study: NCT06028750

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Computer Assisted Surgery
Description: Surgical navigation system (X-Guide guided surgery system) Navigation system X-Guide

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Freehand
Description: Freehand implant placement
Study: NCT04573712

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow up and Assessment
Description: each patient should wear an actigraph during a week and will be do some tests during 2hours (6min walk, apathy inventory, fatigue severity scale etc...)
Study: NCT06399055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-387
Description: 1 Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-387
Description: 1 Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D484
Description: 1 Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D484
Description: 1 Tablet
Study: NCT05822908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VO659
Description: VO659 is an antisense oligonucleotide targeting CAG repeats in mRNA transcripts

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VO659
Description: VO659 is an antisense oligonucleotide targeting CAG repeats in mRNA transcripts

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VO659
Description: VO659 is an antisense oligonucleotide targeting CAG repeats in mRNA transcripts